UTMB team proves potential for reducing pre-term birth by treating fetus as patient
Scientists successfully tested innovative drug delivery system developed by ILIAS Biologics, Inc.
GALVESTON, Texas – The results of a study by researchers at the University of Texas Medical Branch may pave the way for a new medicine delivery system that could reduce the incidence of pre-term labor and premature birth by allowing physicians to treat the ‘fetus as the patient’. The study has been published in Science Advances.
It has long been suspected that pre-term labor is triggered by inflammation caused by a sick fetus. A new study by scientists at UTMB has proved the hypothesis by studying several important assumptions about the relationship between the health of a mother and her unborn child.
According to Dr. Ramkumar Menon, a Professor in UTMB’s Department of Obstetrics and Gynecology and Cell Biology, his team worked with ILIAS Biologics, Inc., a South Korean biotechnology company, to test their bioengineered exosomes as a delivery system for anti-inflammatory medicine directly to the fetus.
“Exosomes are natural nanoparticles or vesicles in our bodies, and we have trillions of them circulating through us at all times. By packaging the medicine inside a bioengineered exosome and injecting it into the mother intravenously, the exosomes travel through the blood system, cross the placental barrier and arrive in the fetus, where they deliver the medicine,” explains Dr. Menon.
In laboratory tests with mice, there were several steps prior to testing the drug delivery. First, Menon said it was important to prove that fetal cells, specifically immune cells, actually migrated through the mother’s body to her uterine tissues as well as to her, which can cause inflammation, the leading cause of pre-term labor.
To prove migration of cells, female mice were mated with male mice who had been genetically engineered with a red fluorescent dye called tdtomato. The dye causes cells in the male to turn red, so once mating has occurred, cells in the developing fetus also turn red and can easily be tracked as they migrate through the mother. This model was developed by Dr Sheller-Miller, a post-doctoral fellow in the Menon lab who is also the first author of this report. Development of this model that determined fetal immune cells reaching maternal tissues was also a turning point in this research.
Once scientists had proof of cell migration, they next used the mouse model to determine if bioengineered exosomes could deliver a special anti-inflammatory medicine, an inhibitor of NF-kB, called super repressor (SR) IkB from the mother’s bloodstream to the fetus.
The exosomes were created using an innovative approach developed by ILIAS Biologics, Inc. called EXPLOR®, or Exosomes engineering for Protein Loading via Optically Reversible protein to protein interaction.
The study proved that the exosomes effectively delivered medicine to the fetus, slowed the migration of fetal immune cells, and delayed pre-term labor.
In addition, the study found that:
* Sustained effects/delays in labor required repeated dosing
* Prolongation of gestation improved pup viability
* Mouse models provided valuable information to help understand the mechanisms often seen in humans
* Future studies, including human clinical trials are needed to confirm laboratory results
“Pre-term birth rates have not reduced in the past few decades, and this technology (the bioengineered exosomes) could lead the way to other treatments for the delivery of drugs to treat the underlying cause of inflammation in a fetus,” said Dr. Menon. This technology can also be used to package other drugs in exosomes to treat other adverse pregnancy complications.
This study result is the second proof of concept that suggests significant anti-inflammatory effects of the same exosomes from ILIAS Biologics. In April 2020, the researchers at Korea Advanced Institute of Science and Technology (KAIST) and the ILIAS team published the same exosomes’ substantial efficacy in the septic mouse model in Science Advances. (Link: https:/
Additional research team members include Samantha Sheller-Miller (first author), Enkhtuya Radnaa and Lauren Richardson of UTMB, Jae-Kwang Yoo, Eunsoo Kim, Kyungson Choi, Youngeun Kim, Una Kim of ILIAS Biologics, Inc., and Chulhee Choi of ILIAS Biologics, Inc and the Korea Advanced Institute of Science and Technology.
The University of Texas Medical Branch
Office of Marketing and Communications
301 University Boulevard, Suite 3.518
Galveston, Texas 77555-0144
ABOUT THE UNIVERSITY OF TEXAS MEDICAL BRANCH: Texas’ first academic health center opened its doors in 1891 and today has fourcampuses, four health sciences schools, fourinstitutes for advanced study, a research enterprise that includes one of only two national laboratories dedicated to the safe study of infectious threats to human health, a Level 1 Trauma Center and a health system offering a full range of primary and specialized medical services throughout the Texas Gulf Coast region. UTMB is an institution in the University of Texas System and a member of the Texas Medical Center.
ABOUT ILIAS Biologics, Inc.:
ILIAS Biologics Inc. was established in 2015 in South Korea to develop exosome-based therapeutics. Its platform technology, EXPLOR™, makes it possible to load large therapeutic molecules into exosomes. ILIAS Biologics Inc. is actively developing various therapeutic exosomes, Exo-Targets®, as potential treatments for sepsis, pre-term birth, and various hard-to-treat diseases in inflammatory, metabolic areas and oncology. To learn more about ILIAS Biologics Inc., visit the website at http://www.
ABOUT EXPLOR® technology:
EXPLOR® technology is a novel protein-loading method that enables active loading of large therapeutic cargo proteins into the lumen of exosomes–nanosized extracellular vesicles–through cellular biogenesis processes. This process involves controllable and reversible detachment of cargo proteins from the membrane of exosomes once they load into exosomes, which increases the ef?ciency of delivery of payload proteins into the cytoplasm or nucleus of target cells. While exosomes have been actively studied as novel therapeutic vehicles for intracellular drug delivery, the controllable loading of therapeutic cargo proteins as free forms in the exosomal lumen has remained a technical hurdle. ILIAS’s technology provides a unique solution to overcome this challenge.